Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling

Proteome Science

Volumn 11, Issue 1, 2013, Pages

  Bai, Ju ^a   He, Aili ^a   Zhang, Wanggang ^a   Huang, Chen ^b   Yang, Juan ^b   Yang, Yun ^a   Wang, Jianli ^a   Zhang, Yang ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Adult acute myeloid leukemia; MALDI TOF MS; Minimal residual disease; Serum peptidome profiling; Weak cation exchange magnetic beads

Indexed keywords

FIBRINOGEN; FIBRINOGEN ALPHA CHAIN PRECURSOR PROTEIN; THROMBOCYTE FACTOR 4; UBIQUITIN; UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME 1; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; UPREGULATION;

EID: 84880860314     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-11-39     Document Type: Article

References (39)

1. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29:475-486. 10.1200/JCO.2010.30.2554, 21220609.
2. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011, 29:495-503. 10.1200/JCO.2010.32.1067, 21220600.
3. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Critic rev oncol/hematol 2004, 50:197-222.
4. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012, 119:332-341. 10.1182/blood-2011-08-363291, 22039260.
5. Martorella A, Robbins R. Serum peptide profiling: identifying novel cancer biomarkers for early disease detection. Acta Biomed 2007, 78:123-128.
6. Albitar M, Potts SJ, Giles FJ, O'Brien S, Keating M, Thomas D, et al. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer 2006, 106:1587-1594. 10.1002/cncr.21770, 16518825.
7. Zou L, Wu Y, Pei L, Zhong D, Gen M, Zhao T, et al. Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis. Leukemia research 2005, 29:1387-1391. 10.1016/j.leukres.2005.04.021, 15936817.
8. Mohamedali A, Guinn B, Sahu S, Thomas N, Mufti GJ. Serum profiling reveals distinctive proteomic markers in chronic myeloid leukaemia patients. British J haematol 2009, 144:263-265.
9. Cui J, Li W, Wang J, Li A, Li H, Wang H, et al. Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 2005, 4:1718-1724. 10.1074/mcp.M400165-MCP200, 16081408.
10. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JTC, Wang HM, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 2005, 51:2236-2244. 10.1373/clinchem.2005.052324, 16239339.
11. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Analytical chemistry 2004, 76:1560-1570. 10.1021/ac0352171, 15018552.
12. Sogawa K, Satoh M, Kodera Y, Tomonaga T, Iyo M, Nomura F. A search for novel markers of alcohol abuse using magnetic beads and MALDI-TOF/TOF mass spectrometry. PROTEOMICS-Clinic Appl 2009, 3:821-828.
13. Ketterlinus R, Hsieh SY, Teng SH, Lee H, Pusch W. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques 2005, 38:37-40.
14. Leung SM, Dikler S, Samuel CM. A new approach for profiling ovarian cancer serum using functionalizied magnetic beads, anchorchip technology, MALDI-TOF MS, MALDI-TOF/TOF MS, and bioinformatics 2003, San Francisco, CA, United States: Presented at the Sixth International Symposium on Mass Spectrometry in the Health and Life Science.
15. Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 2005, 23:5088-5093. 10.1200/JCO.2005.03.164, 16051955.
16. de Noo ME, Mertens BJA, Özalp A, Bladergroen MR, van der Werff MPJ, van de Velde CJH, et al. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur J Cancer 2006, 42:1068-1076. 10.1016/j.ejca.2005.12.023, 16603345.
17. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Investig 2006, 116:271-284. 1323259, 16395409.
18. Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC, et al. Differential capture of serum proteins for expression profiling and biomarker discovery in Pre-and post treatment head and neck cancer samples. Laryngoscope 2009, 118:61-68.
19. He A, Bai J, Huang C, Yang J, Zhang W, Wang J, et al. Detection of serum tumor markers in multiple myeloma using the CLINPROT system. Int J hematol 2012, 95:1-7. 10.1007/s12185-011-0984-7, 22170230.
20. Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, Thiery J. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clinical chemistry 2005, 51:973-980. 10.1373/clinchem.2004.047308, 15845803.
21. Elssner T, Fahr K, Thomas I. Magnetic bead based human plasma profiling to discriminate acute lymphatic leukaemia from non-disease samples. ASMS 2004,
22. Liang T, Wang N, Li W, Li A, Wang J, Cui J, et al. Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment. Proteomics 2009, 10:90-98.
23. Qiu F, Liu H, Zhang X, Tian Y. Optimization of magnetic beads for MALDI-TOF MS analysis. Front Biosci 2009, 14:3712-3723.
24. Zhu W, Smith JW, Huang CM. Mass spectrometry-based label-free quantitative proteomics. BioMed Res Int 2010, 2010:840518.
25. Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle&ast. Cell Death & Differentiation 2005, 12:1191-1197. 10.1038/sj.cdd.4401702, 23943857.
26. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 2004, 40:2217-2229. 10.1016/j.ejca.2004.07.006, 15454246.
27. Scheffner M, Huibregtse JM, Howley PM. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci U S A 1994, 91:8797-8801. 10.1073/pnas.91.19.8797, 44693, 8090726.
28. Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 2010, 115:2251-2259. 10.1182/blood-2009-07-231191, 2920204, 20075161.
29. Tao YL, Li Y, Gao J, Liu ZG, Tu ZW, Li G, et al. Identifying FGA peptides as nasopharyngeal carcinoma-associated biomarkers by magnetic beads. J cellul biochem 2012, 113:2268-2278.
30. Preston T, Slater C, McMillan DC, Falconer JS, Shenkin A, Fearon KCH. Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. J nutrit 1998, 128:1355-1360.
31. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96:3302-3309.
32. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer research 2002, 62:6966-6972.
33. Verheul HMW, van Erp K, Homs MYV, Yoon G, van Der Groep P, Rogers C, et al. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology 2010, 75:608-614. 10.1016/j.urology.2009.05.075, 19683801.
34. Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, et al. Pre-treatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J gastroenterol hepatol 2007, 22:2222-2227. 10.1111/j.1440-1746.2006.04736.x, 18031385.
35. Shi L, Zhang J, Wu P, Feng K, Li J, Xie Z, et al. Discovery and identification of potential biomarkers of pediatric acute Lymphoblastic Leukemia. Proc Natl Acad Sci USA 2009, 7:7.
36. Kim JY, Song HJ, Lim HJ, Shin MG, Kim JS, Kim HJ, et al. Platelet factor-4 is an indicator of blood count recovery in acute myeloid leukemia patients in complete remission. Mol Cell Proteomics 2008, 7:431-441.
37. Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci U S A 2007, 104:1307-1312. 10.1073/pnas.0610330104, 1783137, 17220270.
38. Vermeulen R, Lan Q, Zhang L, Gunn L, McCarthy D, Woodbury RL, et al. Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. Proc Natl Acad Sci USA 2005, 102:17041-17046. 10.1073/pnas.0508573102, 1288009, 16286641.
39. Elssner T, Kostrzewa M. CLINPROT-a MALDI-TOF MS based system for biomarker discovery and analysis. Clinic Proteomics 2006, 8:167.